GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyax Corp (NAS:DYAX) » Definitions » Price-to-Owner-Earnings

Dyax (DYAX) Price-to-Owner-Earnings : (As of May. 07, 2024)


View and export this data going back to . Start your Free Trial

What is Dyax Price-to-Owner-Earnings?

As of today (2024-05-07), Dyax's share price is $38.41. Dyax does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Dyax's Price-to-Owner-Earnings or its related term are showing as below:


DYAX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.19
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-07), Dyax's share price is $38.41. Dyax's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2015 was $-0.21. Therefore, Dyax's PE Ratio for today is At Loss.

As of today (2024-05-07), Dyax's share price is $38.41. Dyax's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.21. Therefore, Dyax's PE Ratio without NRI for today is At Loss.


Dyax Price-to-Owner-Earnings Historical Data

The historical data trend for Dyax's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dyax Price-to-Owner-Earnings Chart

Dyax Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Dyax Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Dyax's Price-to-Owner-Earnings

For the Biotechnology subindustry, Dyax's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dyax's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dyax's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Dyax's Price-to-Owner-Earnings falls into.



Dyax Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Dyax's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=38.41/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dyax  (NAS:DYAX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Dyax Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Dyax's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Dyax (DYAX) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Dyax Corp was incorporated in the state of Delaware in the year 1989, and merged with Protein Engineering Corporation in 1995. It is a biopharmaceutical company focused on Hereditary Angioedema and Other Plasma-Kallikrein-Mediated Disorders and Licensing and Funded Research Portfolio. The Company develops and commercializes treatments for hereditary angioedema and to identify other disorders that are mediated by plasma kallikrein. It is engaged in identifying and developing treatments for patients who experience PKM angioedema. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. Excess plasma kallikrein activity plays a role in HAE and could potentially play a role in a number of inflammatory diseases, including Crohn's disease, psoriasis, rheumatoid arthritis, and various mast cell disorders. It also develops KALBITOR for the treatment of acute attacks of HAE. KALBITOR is currently distributed through a limited network of wholesale, hospital and specialty pharmacy arrangements. Its portfolio of product candidates being developed by licensees using its phage display technology. For KALBITOR as a treatment for HAE, its competitors include: Manufacturers of corticosteroids. Other competitors for the treatment of HAE are companies that are developing small molecule plasma kallikrein inhibitors. The preclinical study and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its products and product candidates, including KALBITOR and those of its licensees, are subject to extensive regulation by governmental authorities in the United States and other countries.
Executives
David J Mclachlan other: Former director ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Gustav Christensen officer: CEO and President, other: Former director DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Todd Bazemore officer: EVP & Chief Commercial Officer C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Thomas L Kempner other: Former director C/O LOEB PARTNERS CORPORATION, 125 BROAD STREET, 14TH FLOOR, NEW YORK NY 10004
Abbie Celniker other: Former director C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142
Marc D Kozin other: Former director
Andrew D. Ashe officer: General Counsel & EVP C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Ron Cohen other: Former director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Mary Ann Gray other: Former director 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
George V Migausky officer: EVP & Chief Financial Officer C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paolo Pucci other: Former director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Burt A Adelman officer: CMO & EVP, R&D DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Ivana Magovcevic-liebisch officer: EVP; Chief Operating Officer 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Susan B Bayh director WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Stephen S Galliker officer: EVP and CFO 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139

Dyax (DYAX) Headlines

From GuruFocus

Dyax Corp. (DYAX) CEO Gustav Christensen buys 5,000 Shares

By GuruFocus Research GuruFocus Editor 09-15-2010

Mario Gabelli Comments on Dyax Corp

By Holly LaFon Holly LaFon 01-29-2016

Dyax Corp. (DYAX) CFO George V Migausky buys 12,000 Shares

By GuruFocus Research GuruFocus Editor 08-25-2010

Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 03-15-2011

Dyax Corp. Reports Operating Results (10-Q)

By gurufocus 10qk 11-02-2010

Mario Gabelli Comments on Dyax Corp

By Holly LaFon Holly LaFon 05-03-2016

Chuck Royce Makes Big Gains on Divestitures

By Samira Meskini Samira Meskini 01-03-2016

Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 03-15-2011